2024
Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks
Rosen L, Thielking A, Dugdale C, Montepiedra G, Kalk E, Kim S, LaCourse S, Mathad J, Freedberg K, Horsburgh C, Paltiel A, Wood R, Ciaranello A, Reddy K. Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks. Clinical Infectious Diseases 2024, ciae508. PMID: 39544107, DOI: 10.1093/cid/ciae508.Peer-Reviewed Original ResearchAdverse pregnancy outcomesHuman immunodeficiency virusRisk of stillbirthFetal/infant deathImmunodeficiency virusHigher risk of LBWMaternal CD4 cell countCD4 cell countMonths of isoniazidRisk of LBWPregnant peopleHigher-risk scenarioTuberculosis preventive treatmentIsoniazid-rifapentineAntiretroviral therapyPregnancy outcomesClinical benefitPrimary outcomeCombined deathPreventive treatmentCell countHigh riskStillbirthPregnancyInternational guidelines
2023
Patterns of Infectious Disease Associated With Injection Drug Use in Massachusetts
Gonsalves G, Paltiel A, Thornhill T, DeMaria A, Cranston K, Klevens R, Warren J. Patterns of Infectious Disease Associated With Injection Drug Use in Massachusetts. Clinical Infectious Diseases 2023, 76: 2134-2139. PMID: 36757712, PMCID: PMC10273381, DOI: 10.1093/cid/ciad073.Peer-Reviewed Original ResearchConceptsSoft tissue infectionsHuman immunodeficiency virusHepatitis C virusInjection drug useHCV casesInfective endocarditisHIV casesDrug useSubstance use disordersLogistic regression modelsClinical sequalaeSSTI casesPublic health crisisTissue infectionsImmunodeficiency virusDisease AssociatedHIV outbreakAbscess incisionC virusUse disordersInfectious diseasesInfectionMultiple outbreaksMedical proceduresSuch associations
2022
Cost‐effectiveness of hepatitis C virus test‐and‐treat and risk reduction strategies among men who have sex with men living with HIV in France
Castry M, Cousien A, Champenois K, Supervie V, Velter A, Ghosn J, Yazdanpanah Y, Paltiel A, Deuffic‐Burban S. Cost‐effectiveness of hepatitis C virus test‐and‐treat and risk reduction strategies among men who have sex with men living with HIV in France. Journal Of The International AIDS Society 2022, 25: e26035. PMID: 36451286, PMCID: PMC9712801, DOI: 10.1002/jia2.26035.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusIncremental cost-effectiveness ratioHigh-risk groupHepatitis C virusHCV screeningRisk reduction strategiesHCV infectionYearly screeningHepatitis C Virus TestRisk reductionHCV screening practicesNew HCV infectionsHigh-risk individualsRisk reduction interventionsCost-effectiveness ratioCost-effective dependingImmunodeficiency virusC virusScreening practicesLifetime horizonScreening frequencyVirus testReduction interventionsRisk behaviorsBehavioral interventions
2017
Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States
Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, Walensky RP. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Internal Medicine 2017, 177: 1613-1621. PMID: 28975270, PMCID: PMC5675744, DOI: 10.1001/jamainternmed.2017.4349.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusLung cancer mortalityAge 40 yearsAntiretroviral therapyLung cancerCancer mortalityLower lung cancer mortalityIncomplete ART adherenceLung cancer deathsAge 80 yearsRisk of deathMortality risk ratioHigher overall mortalityStandard demographic dataGreater AIDSLight smokersSmoking exposureCurrent smokersFormer smokersART adherenceModerate smokersOverall mortalitySmoking habitsSmoking statusImmunodeficiency virusThe Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States
Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. The Journal Of Infectious Diseases 2017, 216: 798-807. PMID: 29029344, PMCID: PMC5853503, DOI: 10.1093/infdis/jix349.Peer-Reviewed Original ResearchConceptsNational HIV/AIDS StrategyIncremental cost-effectiveness ratioHuman immunodeficiency virusCost-effectiveness ratioUS National HIV/AIDS StrategyHIV/AIDS StrategyAntiretroviral therapy costsSubstantial clinical benefitHigh HIV prevalenceGeneral US populationYears of lifeVirologic suppressionViral suppressionClinical outcomesAdherence interventionsClinical benefitHIV prevalenceHIV transmissionImmunodeficiency virusMSM populationAIDS StrategyTherapy costsTreatment targetsUS populationBlack men
2016
Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies
Ouattara EN, Robine M, Eholié SP, MacLean RL, Moh R, Losina E, Gabillard D, Paltiel AD, Danel C, Walensky RP, Anglaret X, Freedberg KA. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clinical Infectious Diseases 2016, 62: 1454-1462. PMID: 26936666, PMCID: PMC4872286, DOI: 10.1093/cid/ciw117.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioAntiretroviral therapyHuman immunodeficiency virusImmunologic failureLaboratory monitoringAIDS Complications-International modelFirst-line antiretroviral therapyBudget impactSecond-line antiretroviral therapyMean CD4 countStandard of careCost-effectiveness ratioLaboratory test costsCD4 monitoringART initiationCD4 countHIV infectionVL monitoringClinical outcomesImmunodeficiency virusCôte d'IvoireMean timeLife expectancyTherapyVL strategies
2015
The Epi-TAF for Tenofovir Disoproxil Fumarate?
Walensky RP, Horn TH, Paltiel AD. The Epi-TAF for Tenofovir Disoproxil Fumarate? Clinical Infectious Diseases 2015, 62: 915-918. PMID: 26658300, DOI: 10.1093/cid/civ1000.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateAverage wholesale priceDisoproxil fumarateBone mineral density lossHIV treatment regimenTenofovir/lamivudineImproved toxicity profileHuman immunodeficiency virusMineral density lossAntiretroviral therapyRenal injuryTenofovir alafenamideTreatment regimenImmunodeficiency virusEqual efficacyToxicity profileCost-effectiveness methodsDensity lossUS residentsAlafenamideRegimenLamivudineTherapyInjuryFumarateThe Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy
Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases 2015, 60: 1102-1110. PMID: 25583979, PMCID: PMC4366583, DOI: 10.1093/cid/ciu1159.Peer-Reviewed Original ResearchConceptsDaily ART adherenceAnnual drug costsART adherenceLA-ARTAntiretroviral therapyDrug costsART-naive patientsDaily oral ARTHIV RNA suppressionSecond-line therapyFirst-line therapyFirst-line regimensHuman immunodeficiency virusDaily ARTOverall life expectancyHIV patientsAdherent patientsAvailable regimensART failureImmunodeficiency virusClinical rolePatientsRNA suppressionTherapyAnnual cost
2013
The Survival Benefits of Antiretroviral Therapy in South Africa
April MD, Wood R, Berkowitz BK, Paltiel AD, Anglaret X, Losina E, Freedberg KA, Walensky RP. The Survival Benefits of Antiretroviral Therapy in South Africa. The Journal Of Infectious Diseases 2013, 209: 491-499. PMID: 24307741, PMCID: PMC3903379, DOI: 10.1093/infdis/jit584.Peer-Reviewed Original ResearchConceptsSecond-line antiretroviral therapyAntiretroviral therapySurvival benefitAIDS Complications-International modelTotal survival benefitT-cell countsHuman immunodeficiency virusART initiationART rolloutUntreated patientsImmunodeficiency virusART availabilitySurvival differencesSuppressive efficacyCohortPatientsTherapyTotal numberRetention ratePersonsBenefitsCost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR, Cohen MS, Freedberg KA. Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. New England Journal Of Medicine 2013, 369: 1715-1725. PMID: 24171517, PMCID: PMC3913536, DOI: 10.1056/nejmsa1214720.Peer-Reviewed Original ResearchConceptsEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapySerodiscordant couplesHIV transmissionHIV Prevention Trials Network 052 studyIncremental cost-effectiveness ratioCost-effectiveness ratioResource-limited settingsHIV infectionClinical benefitImmunodeficiency virusHIV treatmentLonger survivalOpportunistic diseasesEarly initiationFive yearsLifetime outcomesPublic healthSuch personsPatientsPeriodTherapyInfectionDisease
2008
Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival
Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA. Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival. The Journal Of Infectious Diseases 2008, 197: 1324-1332. PMID: 18422445, PMCID: PMC2423492, DOI: 10.1086/587184.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyEligible human immunodeficiency virusEffective antiretroviral therapyHuman immunodeficiency virusNeed of therapyHIV infectionImmunodeficiency virusPatient outcomesAdult cohortDeath rateART scaleTherapyCumulative deathsTreatment slotsDeathRapid scaleHIVPatientsCohortInfectionMortality
2002
Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis
Yazdanpanah Y, Goldie S, Paltiel A, Losina E, Coudeville L, Weinstein M, Gerard Y, Kimmel A, Zhang H, Salamon R, Mouton Y, Freedberg K. Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis. Clinical Infectious Diseases 2002, 36: 86-96. PMID: 12491207, DOI: 10.1086/344902.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioTMP-SMZAntiretroviral therapyHIV diseaseOpportunistic infectionsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex bacteremiaIncremental cost-effectiveness ratioPerson lifetime costsActive antiretroviral therapyEra of HAARTPneumocystis carinii pneumoniaHuman immunodeficiency virusQuality-adjusted life expectancyCost-effectiveness analysisOral ganciclovirCytomegalovirus infectionToxoplasmic encephalitisCarinii pneumoniaImmunodeficiency virusTherapeutic optionsClinical impactFrench patientsProphylaxisInfectionAIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States
Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States. Clinical Infectious Diseases 2002, 35: 606-610. PMID: 12173137, DOI: 10.1086/341903.Peer-Reviewed Original ResearchConceptsEffective antiretroviral therapyHuman immunodeficiency virusDrug Assistance ProgramsCost-effectiveness analysisAntiretroviral therapyHIV careMedication costsImmunodeficiency virusOutpatient arenaDisease outcomePatient's placePrivate health insuranceHealth careHealth insurancePatientsAIDSCareUnited StatesMedicationsHIVInpatientsTherapyMedicaidProphylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. JAMA Internal Medicine 2002, 162: 921-928. PMID: 11966344, DOI: 10.1001/archinte.162.8.921.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-Infective AgentsAntiprotozoal AgentsAtovaquoneCD4 Lymphocyte CountCost-Benefit AnalysisDapsoneDrug CostsHumansLife ExpectancyModels, TheoreticalNaphthoquinonesPentamidinePneumonia, PneumocystisPractice Guidelines as TopicQuality-Adjusted Life YearsConceptsQuality-adjusted life yearsCD4 cell countQuality-adjusted life expectancyPneumocystis carinii pneumoniaCD4 cell count increasePCP prophylaxisCell count increaseCell countCarinii pneumoniaClinical guidelinesCD4 cell count criteriaInitial CD4 cell countCD4 lymphocyte countPrimary PCP prophylaxisActive antiretroviral therapyCohort of HIVHuman immunodeficiency virusTMP/SMXCount increaseAntiretroviral therapyLymphocyte countHIV infectionImmunodeficiency virusTrimethoprim-sulfamethoxazoleProphylaxis
2001
Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts
Yazdanpanah Y, Chêne G, Losina E, Goldie S, Merchadou L, Alfandari S, Seage G, Sullivan L, Marimoutou C, Paltiel A, Salamon R, Mouton Y, Freedberg K. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. International Journal Of Epidemiology 2001, 30: 864-871. PMID: 11511618, DOI: 10.1093/ije/30.4.864.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaPrimary opportunistic infectionCommon opportunistic infectionOpportunistic infectionsCarinii pneumoniaToxoplasmic encephalitisCytomegalovirus infectionIncidence rateGroupe d'Epidémiologie Clinique du SIDAAIDS Reference CenterCD4 lymphocyte declineIncidence of HIVHuman immunodeficiency virusAbsence of prophylaxisHIV risk behaviorsHigh incidence rateHospital-based information systemCandida esophagitisCount declineImmunodeficiency virusLymphocyte declineAntiretroviral drugsClinical guidelinesSpecific infectionsClinical cohortPreevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus
Paltiel A, Goldie S, Losina E, Weinstein M, Seage G, Kimmel A, Zhang H, Freedberg K. Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001, 32: 783-793. PMID: 11229847, DOI: 10.1086/319223.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiviral AgentsChemopreventionCost-Benefit AnalysisCytomegalovirusCytomegalovirus InfectionsGanciclovirHIV InfectionsHumansModels, BiologicalPolymerase Chain ReactionPredictive Value of TestsQuality-Adjusted Life YearsSensitivity and SpecificityValganciclovirConceptsHuman immunodeficiency virusDuration of survivalPreemptive therapyCMV casesImmunodeficiency virusCMV polymerase chain reactionEnd-stage HIV diseaseUpcoming trialsCMV preemptive therapySalvage antiretroviral therapyCells/microLClinical trial dataCMV prophylaxisAntiretroviral therapyHIV diseaseComplication rateEfficacy assumptionsPolymerase chain reactionDisease progressionClinical uncertaintyDrug effectsPatientsTrial dataTherapyChain reaction